ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer
January 9, 2023
The ADARx Team
SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Robert MacLeod, Ph.D. as Chief Scientific Officer.
“I am delighted to welcome Robert to ADARx with his extensive experience in the oligonucleotide field,” said Dr. Zhen Li, President, and Chief Executive officer of ADARx. “As ADARx continues to grow, Robert will help to drive the evolving research and development needs of our organization. Robert’s experience in the discovery and development of RNA therapeutics across multiple therapeutic areas supports our goal of turning cutting-edge science into life-saving therapeutics.”
Dr. MacLeod joins ADARx as ADX-324 for the treatment of hereditary angioedema is currently enrolling healthy volunteers for its phase I clinical trial. ADARx has two additional drug candidates set to enter clinical trials in 2023 and an extensive pipeline to follow. Prior to ADARx, Dr. MacLeod served as the Chief Scientific Officer at Flamingo Therapeutics after holding several positions at Ionis Pharmaceuticals, most recently as Vice President and Franchise Head of Oncology. He has led the strategic and scientific efforts of several multidisciplinary drug discovery teams leading to the discovery and clinical development of 15 novel investigational therapeutics and over 100 high impact scientific publications and patents. Dr. MacLeod received his B.S. in Chemistry and Biochemistry from Concordia University in Montreal Canada, and his Ph.D. in Cancer Epigenetics from McGill University.
“It’s an exciting time in RNA therapeutics and I believe ADARx will be a leader in this space with its broad approach to discovering and developing novel therapies,” said Dr. MacLeod. “I look forward to contributing to the impressive advances in the ADARx platforms that have already generated its first clinical stage program and a deep discovery pipeline in the Company’s still short history.”
ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases.